Biomarker evaluation including sTIL, AR, Ki-67 and PD-L1 was performed on core biopsy materials as a representation of the entire tumor; therefore, limited sampling is an intrinsic limitation of this neoadjuvant study. This evidence concerns the gene MKI67 and neoplasm.